DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, shared its financial results for 2024 and provided a progress update on its lead programs aimed at advancing cancer care. With innovative approaches like the WEE1 kinase inhibitor APR-1051 and the ATR inhibitor ATRN-119, the company is focusing on unmet medical needs in difficult-to-treat cancers.
“We made excellent progress across our pipeline in 2024, laying a strong foundation for the year ahead,” said Oren Gilad, Ph.D., President and CEO of Aprea. “Our ultimate goal is to transform the treatment paradigm for difficult-to-treat cancers by unlocking the full potential of DDR-based therapies.”
Clinical Progress
ACESOT-1051 Trial (APR-1051)
The ACESOT-1051 trial evaluates Aprea’s WEE1 kinase inhibitor, APR-1051, which aims to address tolerability challenges experienced with other WEE1 inhibitors. The trial, now enrolling Cohort 5 participants at a 70 mg dose, has shown no hematological toxicities to date, supporting its potential as a safe and effective treatment option. APR-1051 is being studied particularly in cancers with Cyclin E over-expression, which currently lack effective therapeutic options. Open-label safety and preliminary efficacy data are expected in the second half of 2025.
ABOYA-119 Trial (ATRN-119)
Aprea’s ATRN-119, a macrocyclic ATR inhibitor, is being tested in the ABOYA-119 trial for patients with advanced solid tumors that harbor mutations in DDR-related genes. The study has progressed to Dose Level 7, evaluating both once-daily and twice-daily dosing regimens to maximize therapeutic benefits. The twice-daily approach is expected to optimize target coverage and improve clinical outcomes.
Financial Performance
For the year ending December 31, 2024, Aprea reported a net loss of $13.0 million, an improvement from the $14.3 million loss in 2023. Research and development expenses increased to $9.4 million, reflecting expanded clinical activity, while general and administrative costs decreased to $6.5 million due to reduced severance expenses and lower insurance premiums.
Cash and cash equivalents totaled $22.8 million as of December 31, 2024, up slightly from $21.6 million at the end of 2023. The company projects that its financial resources will support operations through the first quarter of 2026.
Outlook
Aprea is positioned to deliver significant results in 2025 as data from its ongoing clinical trials emerge. The company’s focus on addressing unmet needs in cancer care aligns with its broader goal of providing innovative therapies to improve patient outcomes. With APR-1051 and ATRN-119 making steady progress, Aprea continues to advance DDR-based treatments that hold the potential to redefine cancer management.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.